Audrey Gabelle
Overview
Explore the profile of Audrey Gabelle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
3410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butler P, Yang J, Brown R, Hobbs M, Becker A, Penalver-Andres J, et al.
Nat Med
. 2025 Mar;
PMID: 40038507
Consumer-grade mobile devices are used by billions worldwide. Their ubiquity provides opportunities to robustly capture everyday cognition. 'Intuition' was a remote observational study that enrolled 23,004 US adults, collecting 24 ...
2.
Delaby C, Alcolea D, Busto G, Gabelle A, Ayrignac X, Bennys K, et al.
Alzheimers Res Ther
. 2025 Feb;
17(1):42.
PMID: 39948603
Background: Blood-based assays are expected to be integrated into clinical routines across various contexts, including Alzheimer's disease (AD). Vascular dementia (VaD), which is the second most common cause leading to...
3.
Lehmann S, Gabelle A, Duchiron M, Busto G, Morchikh M, Delaby C, et al.
medRxiv
. 2025 Jan;
PMID: 39830279
Importance: Early detection of brain amyloidosis (Aβ+) is pivotal for diagnosing Alzheimer's disease (AD) and optimizing patient management, especially in light of emerging treatments. While plasma biomarkers are promising, their...
4.
Decaix T, Mouton-Liger F, Dumurgier J, Cognat E, Vrillon A, Hugon J, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100009.
PMID: 39800467
Background: The use of cerebrospinal (CSF) biomarkers in the diagnosis of Alzheimer's disease (AD) has been gaining interest in clinical practice. Although their usefulness has been demonstrated, their potential value...
5.
Lehmann S, Schraen-Maschke S, Buee L, Vidal J, Delaby C, Hirtz C, et al.
Mol Neurodegener
. 2024 Oct;
19(1):66.
PMID: 39380095
Background: Current AT(N) stratification for Alzheimer's disease (AD) accounts for complex combinations of amyloid (A), tau proteinopathy (T) and neurodegeneration (N) signatures. Understanding the transition between these different stages is...
6.
Blum D, Cailliau E, Behal H, Vidal J, Delaby C, Buee L, et al.
Alzheimers Dement
. 2024 Aug;
20(10):6948-6959.
PMID: 39099181
Introduction: We investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients. Methods: MCI (N ...
7.
Lista S, Imbimbo B, Grasso M, Fidilio A, Emanuele E, Minoretti P, et al.
J Neuroinflammation
. 2024 Jul;
21(1):187.
PMID: 39080712
Background: Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with...
8.
Lehmann S, Vialaret J, Gabelle A, Bauchet L, Villemin J, Hirtz C, et al.
Bioinformatics
. 2024 Jul;
40(8).
PMID: 39078204
Motivation: The knowledge of protein dynamics, or turnover, in patients provides invaluable information related to certain diseases, drug efficacy, or biological processes. A great corpus of experimental and computational methods...
9.
Giroux P, Vialaret J, Kindermans J, Gabelle A, Bauchet L, Hirtz C, et al.
J Proteome Res
. 2024 Jun;
23(7):2408-2418.
PMID: 38857467
The analysis of protein dynamics or turnover in patients has the potential to reveal altered protein recycling, such as in Alzheimer's disease, and to provide informative data regarding drug efficacy...
10.
Lehmann S, Schraen-Maschke S, Vidal J, Delaby C, Buee L, Blanc F, et al.
J Neurol Neurosurg Psychiatry
. 2024 Apr;
95(11):1046-1053.
PMID: 38658136
Background: Among plasma biomarkers for Alzheimer's disease (AD), pTau181 and pTau217 are the most promising. However, transition from research to routine clinical use will require confirmation of clinical performance in...